



- (51) International Patent Classification:
G01R 33/20 (2006.01)
- (21) International Application Number:
PCT/US2015/026919
- (22) International Filing Date:
21 April 2015 (21.04.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/981,878 21 April 2014 (21.04.2014) US
- (71) Applicant: RENNELAER POLYTECHNIC INSTITUTE [US/US]; 110 8th Street, J Building, Troy, NY 12180 (US).
- (72) Inventors: WANG, Ge; 20 Hilander Drive, Loudonville, NY 12211 (US). GETZIN, Matthew, Webber; 151 4th St., Apt. 3A, Troy, NY 12180 (US). GJESTEBY, Lars, Arne; 8 Tad Lane, Cohasset, MA 02025 (US). CONG, Wenxiang; 9 Keystone Ct., Albany, NY 12205 (US).
- (74) Agents: FRANK, Louis, C. et al.; Saliwanchik, Lloyd & Eisenschecnk, P.O. Box 142950, Gainesville, FL 32614-2950 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NANOPARTICLE-ENABLED X-RAY MAGNETIC RESONANCE IMAGING (NXMRI)




FIG. 24

(57) Abstract: Imaging systems and methods are provided. Systems and methods of the subject invention can include the use of nanoparticles (for example, nanophosphors) within a sample to be imaged. Excitation with radiation, such X-ray radiation, can be performed on the nanoparticles to give rise to a change in one or more resonance parameters of the nanoparticles, and this change can be measured using magnetic resonance imaging to provide localization information.

DESCRIPTION

NANOPARTICLE-ENABLED X-RAY MAGNETIC RESONANCE IMAGING (NXMRI)

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application Serial No. 61/981,878, filed April 21, 2014, which is incorporated herein by reference in its entirety.

BACKGROUND OF INVENTION

The study of biological systems is a complex pursuit that requires sufficient models and tools to measure responses to controlled changes in the system. Such models include simulations, two-dimensional (2D) and three-dimensional (3D) *in vitro* constructs, and *in vivo* animal and human models. These can be studied at varying levels of scale that span from molecular to whole-organism behavior. To measure changes on the smaller end of the scale, imaging tools including microscopes and *in vivo* bio-imaging modalities, as well as nucleic acid and protein quantification tools, can be utilized. These tools can be especially useful in regenerative medicine studies where slight changes on the cellular and molecular level can induce radical changes in the overall model. Therefore, correct use of the imaging tools for accurate assessment of constructs is of utmost importance.

Optical imaging methods such as microscopy have dominated the realm of 2D cellular and molecular imaging research. Microscopy has allowed for much insight into the mechanisms of cellular and molecular function. However, these insights have been limited to 2D and thin 3D models because of the diffusive properties of optical light. In order to study more complex systems with 3D interactions, imaging modalities must evolve to allow for deeper imaging. Computed tomography (CT) and magnetic resonance imaging (MRI) are two well-established modalities that are capable of imaging deep tissues that elude optical methods. CT uses an X-ray source to irradiate a region of interest. X-ray detectors are set up on the other side of the sample and can measure both the power and the spectra of the X-rays that transverse the sample. Contrast occurs due to the varying attenuation that different tissue types have on the X-rays. MRI, on the other hand, uses large homogeneous magnetic fields and strategic radio frequency (RF) pulse sequences to determine the concentration and surrounding environment for nuclei of interest. The value of a single

voxel is the vector sum of the magnetic resonance of all of the nuclei of interest in a given volume.

Chemical shift-based MRI methods are often used to separate water and fat signals from the acquired images. The mechanism on which this method is based is the variation in the local magnetic fields for the nuclei of interest. In the case of fat-suppression MRI, the H1 proton of lipid rich tissues has a different magnetic resonance than that of the H1 proton in water. This difference (chemical shift) is measured in parts per million and depends on the chemical environment of the given isotope.

Conventional forms of molecular imaging, such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and fluorescence resonance energy transfer (FRET), offer extremely high specificity in imaging and increase understanding of some molecular functionality. Despite these strengths, however, they are limited in their spatial and temporal resolution. Fluorescence-based imaging, especially, has limitations in terms of imaging depth.

BRIEF SUMMARY

The subject invention provides novel and advantageous imaging systems and imaging methods, capable of overcoming the limitations of related art imaging methods and systems. Systems and methods of the subject invention can include the use of nanoparticles (for example, nanophosphors) within a sample to be imaged. Excitation with radiation, such as ultraviolet (UV) or X-ray radiation, can be performed on the nanoparticles to affect one or more resonance parameters of the nanoparticles. That is, after excitation, the change in energy state of the nanoparticles can affect the local magnetic fields surrounding the nanoparticles, and, when in a magnetic resonance imaging (MRI) machine, this change can be measured as a change in one or more resonance constants (for example, T1, T2, and/or T2*) of the nanoparticles. This can provide localization information in imaging (including but not limited to *in vivo* imaging such as brain, cardiac, and cancer imaging) as a long-term, dynamic contrast agent.

In an embodiment, an imaging method can include: providing nanoparticles to a sample to be imaged; using a radiation source to excite the nanoparticles; and imaging the sample using MRI to obtain localization information of the nanoparticles by measuring a

change in a resonance parameter of the nanoparticles as a result of the excitation by the radiation source.

In another embodiment, an imaging system can include: a radiation source configured to supply radiation to nanoparticles provided within a sample to be imaged; an MRI machine configured to obtain a magnetic resonance image of the sample before and after excitation by the radiation source; and a processor configured to determine localization information of the nanoparticles provided within the sample by measuring a change in a resonance parameter of the nanoparticles as a result of the excitation by the radiation source.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows an energy diagram of doped semiconductors for stored nanophosphor luminescence.

Figure 2A shows a plot of persistent luminescence intensity versus time.

Figure 2B shows near-infrared (NIR) images of four phosphor discs taken at different persistent luminescence times.

Figure 3 shows optical emission spectra for nanoparticles.

Figure 4 shows a schematic view of nanoparticle-enabled X-ray magnetic resonance imaging.

Figure 5 shows an image of phosphorescent powders.

Figure 6 shows an image of tubes having phosphorescent powders.

Figure 7 shows a plot of T_2 relaxation time.

Figure 8 shows an image of phosphorescent powders.

Figure 9 shows an image of nanoparticles.

Figure 10 shows an image of tubes having nanoparticles and tubes having water.

Figure 11 shows an image of tubes having nanoparticles and tubes having water.

Figure 12 shows a schematic view of a tube having nanoparticles.

Figure 13 shows a plot of T_2 relaxation time.

Figure 14A shows an image of tubes having nanoparticles and tubes having water in a pre-excitation state.

Figure 14B shows an image of tubes having nanoparticles and tubes having water in a post-excitation state.

Figure 15 shows an image of an MRI machine.

Figure 16 shows an image of tubes having nanoparticles.

Figure 17 shows an image of tubes having nanoparticles being inserted into an MRI machine.

Figure 18 shows an image of tubes having nanoparticles and tubes having water.

Figure 19 shows images of tubes having nanoparticles and tubes having water.

Figure 20 shows an image of tubes having nanoparticles and tubes having water.

Figure 21A shows a plot of T_2 relaxation time for settled nanoparticles.

Figure 21B shows a plot of T_2 relaxation time for bulk water.

Figure 22 shows an image of tubes having nanoparticles and tubes having water.

Figure 23A shows a plot of T_2 relaxation time for settled nanoparticles.

Figure 23B shows a plot of T_2 relaxation time for bulk water.

Figure 24 shows a schematic view of a system according to an embodiment of the subject invention.

Figure 25A shows a scheme demonstrating persistent nanophosphors.

Figure 25B shows a scheme demonstrating persistent nanophosphors.

Figure 26 shows a schematic view of a combined computed tomography-magnetic resonance imaging (CT-MRI) scanner according to an embodiment of the subject invention.

Figure 27 shows an image of gradient coils of an MRI scanner.

Figure 28 shows an image of modulated X-rays for localization.

Figure 29 shows images of nanoparticles within tubes.

Figure 30A shows a side view of capillary tubes having nanoparticles and tubes having water.

Figure 30B shows a side view of capillary tubes having nanoparticles and tubes having water.

Figure 30C shows a schematic view of capillary tubes having nanoparticles and tubes having water.

Figure 31A shows a microscopy image of UV pre-excited nanophosphor powder with laser stimulation off.

Figure 31B shows a microscopy image of the UV pre-excited nanophosphor powder of Figure 40A, with laser stimulation on.

Figure 32A shows an image of nanophosphors and a bar graph showing mean T_2 relaxation time.

Figure 32B shows an image of a control sample before excitation.

Figure 32C shows an image of the control sample of Figure 32B after excitation.

Figure 33 shows a diagram of image analysis according to an embodiment of the subject invention.

Figure 34A shows an image of nanophosphors and a bar graph showing mean T_2 relaxation time.

Figure 34B shows an image of a sample before excitation.

Figure 34C shows an image of the sample of Figure 34B after excitation.

Figure 35A shows an image of nanophosphors and a bar graph showing mean T_2 relaxation time.

Figure 35B shows an image of a sample before excitation.

Figure 35C shows an image of the sample of Figure 35B after X-ray excitation.

Figure 36A shows an image of nanophosphors and a bar graph showing mean T_2 relaxation time.

Figure 36B shows an image of a sample before excitation.

Figure 36C shows an image of the sample of Figure 36B after X-ray excitation.

Figure 37 shows an image of nanoparticles (top left), a bar graph showing mean T_2 relaxation time (top right), and images of samples.

Figure 38 shows an image of nanoparticles (top left), a bar graph showing mean T_2 relaxation time (top right), and images of samples.

Figure 39A shows an image of nanoparticles and a bar graph of an unexcited control.

Figure 39B shows an image of nanoparticles and a bar graph of a UV-excited sample.

Figure 39C shows an image of nanoparticles and a bar graph of an X-ray-excited sample.

Figure 39D shows an image of nanoparticles and a bar graph of an X-ray-excited sample.

Figure 40 shows an image resulting from subtracting an image without UV from an image with UV.

Figure 41 shows a plot of T_2 relaxation times.

DETAILED DESCRIPTION

The subject invention provides novel and advantageous imaging systems and imaging methods, capable of overcoming the limitations of related art imaging methods and systems. Systems and methods of the subject invention can include the use of nanoparticles (for example, nanophosphors) within a sample to be imaged. Excitation with radiation, such as ultraviolet (UV) or X-ray radiation, can be performed on the nanoparticles to affect one or more resonance parameters of the nanoparticles. That is, after excitation, the change in energy state of the nanoparticles can affect the local magnetic fields surrounding the nanoparticles, and, when in a magnetic resonance imaging (MRI) machine, this change can be measured as a change in one or more resonance constants (for example, T1, T2, and/or T2*) of the nanoparticles. This can provide localization information in imaging (including but not limited to *in vivo* imaging such as brain, cardiac, and cancer imaging) as a long-term, dynamic contrast agent. Nanoparticles can reach and remain in areas of a body (e.g., a human body) that conventional contrast fluids may not be able to (for example, through the blood brain barrier).

The subject invention provides multi-physics coupling techniques. Through the combination of certain techniques, including radiation (e.g., X-ray or UV) excitable nanoparticles, chemical shift imaging, and/or interior tomography, the subject invention provides new approaches for molecular imaging without the limitations of related art methods. In certain embodiments, principles of computed tomography (CT) can be combined with MRI; for example, a combined CT-MRI scanner can be used for simultaneous or nearly simultaneous excitation and imaging.

In many embodiments, resonance parameters (e.g., T1, T2, and/or T2*) of nanoparticles can be modulated by excitation of the nanoparticles by irradiating (e.g., UV or X-ray irradiation) the nanoparticles. For example, the T2 relaxation time of nanoparticles can be modulated by X-ray excitation and measured by MRI. Irradiation-excited (e.g., X-ray-excited) nanophosphors simultaneously enable high-resolution imaging, biological targeting, and enhanced MRI soft tissue contrast *in vivo* or *in situ*. The nanoparticles can be nanophosphors, though embodiments are not necessarily limited thereto. The nanophosphors can be semiconducting crystals, which can be doped (e.g., with lanthanide ions), though embodiments are not limited thereto. Nanophosphors that can be used can include, for example, LiGa_5O_8 (which can be doped with, e.g., Cr^{3+}), MgGa_2O_4 (which can

be doped with, e.g., Cr^{3+}), $\text{CaMgSi}_2\text{O}_6$ (which can be doped with Eu^{2+} , Mn^{2+} , or Pr^{3+}), or $\text{Gd}_2\text{O}_2\text{S}$ (which can be doped with, e.g., Tb^{3+}), though embodiments are not limited thereto.

Irradiation-excited (e.g., X-ray-excited) electrons in nanophosphors can change the local magnetic field in a measurable way, which can specifically lead to measurable changes in resonance parameters, such as MRI relaxation parameters, before and after excitation. This technique can be referred to as nanoparticle-enabled excitation MRI or nanoparticle-enabled X-ray MRI (NXMRI) can synergistically blend merits of optical imaging, CT, and MRI. Imaging hardware capable of simultaneous CT-MRI imaging can be used, or separate devices for excitation and MRI can be used.

Although CT and MRI have seemingly contradicting acquisition mechanisms (CT-spinning metal detectors, MRI-large magnetic field), the datasets of CT and MRI can be quite complimentary. Also, in a simultaneous acquisition system, the imaging physics of CT and MRI can be used to alter the imaged system and, therefore, the acquired signal for new information not previously known. Systems and methods of the subject invention can apply this concept of multi-physics coupling as a means for targeted, high resolution (spatial, contrast, and temporal) imaging. Nanoparticles can be used as a coupling mechanism between different imaging modalities (e.g., CT and MRI). In certain embodiments, the nanoparticles can be made of doped semiconducting materials that store energy in the form of high energy electrons after irradiation by high energy electromagnetic radiation. The irradiation can be, e.g., UV or X-ray irradiation. After excitation, the change in energy state in the nanoparticles can affect the local magnetic fields surrounding the nanoparticles. When placed in an MRI machine, this can be measured as a change in the resonance constants (e.g., T_1 , T_2 , and/or T_2^*). This can allow for faster scanning as focused CT can provide a mechanism of knowing spatial information of an object being imaged without the need for all the complex and time-consuming magnetic gradients that are used in related art MRI technologies. CT can also offer superior combinations of spatial resolution and imaging speed compared to MRI, and by combining the modalities and using highly specific targeted nanoparticles, spatial, contrast, and temporal resolution can be achieved on levels not previously achieved in *in vivo* imaging.

Systems and methods of the subject invention can advantageously allow for simultaneous acquisition (e.g., using CT and MRI), giving high correlation between the images obtained by both systems to be linked with use of nanoparticles. Because the

information seen in CT and MRI are different yet can work together synergistically, simultaneous acquisition can remove the limitations of combining their information, which includes delays in acquisition between modalities, motion artifacts, and poor slice/ROI (region of interest) registration. By coupling these systems, the acquisition physics of each modality can advantageously be used to induce the information measured by the other method. This multi-physics coupling can be seen as an effect of the large magnetic fields on the X-ray scattering within the system or as changes in the local resonance constants (T_1 , T_2 , T_2^*) due to X-ray radiation (e.g., in biological tissues). The subject invention can allow for spatial information to be obtained much faster than related art technologies; this can be done by largely bypassing the need for gradient coils and frequency and phase encoding. Focused irradiation (e.g., focused X-ray beams) can be used for excitation, giving a high level of control over where the irradiation is focused and, therefore, where the local magnetic field changes occur. The irradiation energy (e.g., X-ray energy) can be highest in the focal spot of the beam, but energy can be deposited and distributed into the tissue in “gradient-like” fashion, giving rise to spatially varying resonance changes without the need for the gradient coils. In certain embodiments, an exogenous material can be introduced to the system to change the measurable signals in a way that can be predicted.

In an embodiment, a CT-MRI scanner can be used for nanoparticle-based CT-MRI coupling for imaging, radiation therapy, and research, among other applications. A system can include magnets, such as permanent magnets to form a regionally uniform magnetic field while leaving room for a stationary CT gantry. For example, a double donut-shaped pair of permanent magnets can form a regionally uniform magnetic field (e.g., about 0.5 Tesla) and leave room for a stationary 9-source interior CT gantry at 3 tube voltages (triple-energy CT). Spatiotemporal correlation of complicated features and multi-physics coupling based parameters can be extracted. In another embodiment, nanoparticles, X-ray imaging, and MRI can be integrated. Because X-rays modulate distributions of electrons inside nanoparticles and change MRI parameters (e.g., T_2), improved imaging can be achieved as discussed herein. In another embodiment, single or multiple X-ray beams can be combined with a simplified magnetic setup for NXMRI. Embodiments of the subject invention provide synergy from synchrony and coupling that can advantageously benefit many fields, including biomedicine.

Nanoparticles can be used in a variety of biomedical applications, including drug

delivery and medical imaging. The chemistry of these particles can be controlled for highly specific targeting using antibodies. Functionalization in this way can allow for the nanoparticles to act as probes for cellular and molecular imaging. Through functional-group customization, the nanoparticles can be adjusted based on the application, region, molecule, tissue, or cell type of interest. Also, in the same way that the proton resonance of fat and water vary, so too should the resonance of given nuclei of a nanoparticle at low- and high-energy states.

In addition to their targeting ability, nanoparticles can be designed to perform a number of functions including drug delivery to imaging enhancement. One class of image enhancement nanoparticles that can be particularly useful is the nanophosphor group of nanoparticles. These particles can be made of inherent semiconducting molecules and subsequently doped with rare earth ions. This type of formulation gives the manufacturer the ability to use some form of electromagnetic (EM) radiation (e.g., visible light, ultraviolet (UV), X-ray) to excite the nanoparticles and induce a “trapping” of high energy electrons between the valence and conducting bands of the electron shell. Over time or after subsequent stimulation of the excited nanophosphor (NP) with another form of EM radiation, the energy can be released as light (luminescence), such as visible or near-infrared (NIR) light. The energy of these electrons and the persistence (length of time) of the trap can be customized by changing the nanoparticle formulation and/or doping ion. Types of energy storage that can be achieved by nanophosphors include immediate luminescence, persistent luminescence, and stored luminescence with stimulated release.

Nanophosphors that exhibit immediate release of the transferred energy in the form of luminescence can be said to have immediate luminescence. Persistent luminescence nanoparticles refer to a type of nanoparticle that can absorb EM radiation at wavelengths specific to its chemical and physical properties, and remain in that higher energy state for prolonged periods of time. Compositions of such nanoparticles can vary slightly, though some commonly used chemistries include $\text{MgGa}_2\text{O}_4:\text{Cr}^{3+}$ and $\text{CaMgSi}_2\text{O}_6:\text{Eu}^{2+}, \text{Mn}^{2+}, \text{Pr}^{3+}$. The commonality of these energy-storing nanoparticles is the presence of the rare earth ions. These can act as electron traps whose optical properties can be adjusted through the addition of more doping ions, effectively “deepening” the trap. Figure 1, which shows an energy diagram of doped semiconductors for stored nanophosphor luminescence, illustrates this process. The persistence of the luminescence that these excitable nanophosphors are capable

of emitting is evidence of energy storage of such nanoparticles. Irradiated nanophosphors can exhibit persistent luminescence for up to 1,000 hours after excitation (Liu *et al.*, 2013); Figures 2A and 2B summarize the results of Liu *et al.* (2013). Figure 2A shows an NIR persistent luminescence decay curve monitored at 716 nm after irradiation by 300-nm light for 20 minutes. The discs persistent luminescent $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$ phosphor discs. Figure 2B NIR images of four persistent luminescent $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$ phosphor discs taken at different persistent luminescence times (10 minutes to 1,008 hours) after irradiation by a 254-nm lamp for 10 seconds to 5 minutes.

Energy transfer mechanisms for these nanoparticles can be highly dependent on the particle composition, but they can be excited with both UV and X-ray radiation. Various silicon nanostructures can absorb energy such that their excited state has an increase of about 2 - 7 eV over resting state particles. This change in energy is directly related to the fluorescent emissions that can be seen immediately or elicited at later time points from subsequent excitation with NIR radiation. The optical emission spectra of lutetium oxide nanoparticles after UV excitation are displayed in Figure 3. Figure 3 shows the optical emission spectra for Lu_2O_3 : 2.5 at % Eu^{3+} , 1.0 at % Bi^{3+} after excitation from 330 nm UV light. This fluorescence emission can be attributed to an increase in energy that redistributes the nanoparticle's electrons within its energy shells. This change in energy can be measurable in changes in the nanoparticle's resonance characteristics.

Beam geometry is a consideration when exciting nanophosphors with X-rays in a target region, such as a target region of a body (e.g., a brain). Fan beam and pencil beam geometries offer precise targeting of biology, but they are best suited for 2D imaging purposes. For the targeting of nanophosphors in the body, precise 3D beam geometry is preferable while minimizing radiation. The method of interior tomography can help deal with such a challenge. Interior tomography enables exact reconstruction of an internal region of interest (ROI) while requiring only the projection data through that ROI. The geometry used in interior CT is spiral cone-beam. This facilitates narrower beams, eliminates unnecessary radiation, and reduces scan times as compared to global tomographic reconstruction. Because specificity is of utmost importance when passing X-rays through a body (e.g., a human body), the principles of interior CT offer a benchmark in the excitation of nanophosphors in the brain.

Micro-modulated luminescence tomography (MLT) and stored luminescence computed tomography (SLCT) are multi-modality tools that utilize the penetration depth of CT and the specificity of optical molecular probes. Both of these mechanisms require the sample to be exposed to X-ray excitable nanoparticles. These nanoparticles can be specifically designed to attach to a certain cell type or protein. Once the nanoparticles have been given time to distribute and attach to their target molecules, an X-ray source can be focused on the ROI and used to excite the nanoparticles to a high-energy state. The nanoparticles can remain at this high energy state for hours at a time or, through NIR excitation, the energy can be released as optical energy in the NIR range. However, because the measured signal is still in the optical range, penetration depth remains an issue.

MLT and SLCT technologies can allow for enhancing resolution of acquired data in comparison to conventional molecular imaging techniques. These techniques can use doped semiconductors that can be tagged to specifically bind to the area of interest. Through strategic collimation and focusing of the X-ray source, nanoparticles in specified areas of interest can be excited with a relatively low X-ray dose. This allows for a whole new level of imaging specificity. MLT and SLCT can use optical pairing in order to acquire the luminescent signal from the excited nanoparticles. These techniques, despite their increased penetration depth compared to techniques such as FRET, may still be limited in this area. Therefore, the systems and methods of the subject invention can provide advantages over existing imaging modalities.

Chemical shift imaging methods can be used to separate water and fat signals from acquired MRI data. Because the molecular structure of the hydrogen protons of fat and of water are different, a shift in the resonant frequency of these protons results. This shift can cause a misrepresentation of the location of fatty signals relative to the water signals. In addition to this difference in resonant (Larmor) frequency, spin relaxation times (T_1 , T_2 , and T_2^*) can also be affected by the surrounding electric and magnetic environment (i.e., protons in fat versus protons in water). Radio frequency (RF) pulse sequences can be adjusted to isolate water and fat signals. These same principles can be applied to other endogenous nuclei of interest, including phosphorus-31 and carbon-13. Chemical shifts in phosphorus-31 nuclei can enable detection of alterations in cardiac phosphate metabolism. Similarly, exogenous molecules, such as nanoparticles, can be used as the target nuclei in magnetic resonance chemical shift imaging.

In many embodiments of the subject invention, nanoparticle-mediated X-ray magnetic resonance imaging (NXMRI) can use X-ray excited nanophosphors in chemical shift-based MRI. Nanophosphors can enable imaging (e.g., biological imaging such as brain imaging) at depths unattainable by existing techniques. Energy storing nanoparticles can be used with optical imaging to image nanophosphor distribution in depths of greater than 5 mm (e.g., such depths in a brain). While a depth of 5 mm is much deeper than current microscopy techniques including electron microscopy, it still only accounts for the cortex of the brain. Using MRI, deeper regions containing nanophosphors can be imaged and analyzed according to embodiments of the subject invention, based on changes in their spin relaxation properties due change in energy state induced by X- ray irradiation. Relaxation time T2 (or T_2), also referred to as transverse or spin-spin relaxation time, can show the largest difference. The effects that X-ray excitation has on the T2 property of nanophosphors during MRI show that NXMRI can have a wide range of applications.

Figure 4 shows a schematic view illustrating the mechanism of NXMRI according to certain embodiments of the subject invention. Referring to Figure 4, nanoparticles can be excited by X-rays, causing stored and/or persistent luminescence of the nanophosphors. MRI can be used to measure the change in resonance characteristics (e.g., relaxation time such as T2 relaxation time) of the nanophosphors before and after excitation. Though Figure 4 shows that a permanent magnet with a 0.5 Tesla (T) field is used, this is for exemplary purposes only; embodiments of the subject invention are not limited thereto.

The ability to distinguish signals from low- or high-energy nanoparticles can depend on a number of factors. One factor is the effective range between the respective Larmor frequencies of the low- and high-energy nanoparticles. Resonance in porous silicon-based nanoparticles can increase in high-energy nanoparticles on the order of hundreds of THz (same frequency as emitted radiation). The larger the difference between the spectra of these two states, the more accurate separation of signal can be achieved. The ability to use frequency encoding for spatial mapping is another important consideration. Because the Larmor frequencies may differ slightly between low- and high-energy state nanoparticles, the spatial registration of the resulting signals can vary between acquisitions. This can largely be compensated for via various image analysis algorithms. Additionally, interior tomography principles can be applied to MRI in order to improve spatial and temporal resolution of chemical shift imaging. This can be achieved by using a time-varying gradient magnetic

field in an area that includes only the ROI, while maintaining a homogeneous main magnetic field elsewhere.

Embodiments of the subject invention, including NXMRI, have many high impact applications, including improving imaging techniques that can be used to map and collect functional data in vivo, including data of the brain (e.g., a human brain). Deep signal extraction is a challenge in brain imaging, and embodiments of the subject invention provide solutions to this challenge. Because both X-rays and radio waves are easily transmittable through the skull and brain tissue, the excitation and measurement of nanoparticles (e.g., nanophosphors) can be done in areas that often cannot be studied with current technology. In addition to brain imaging, cancer detection and treatment monitoring can also benefit from embodiments of the subject invention. The nanoparticles (e.g., nanophosphors) can serve as a contrast agent to be introduced to regions of the body that are challenging to reach, such as the prostate. Chemical shift imaging can be effective in detecting prostate cancer tumors. Because about 20% of prostate cancers develop in the transition zone, which is the region of the prostate surrounding the proximal urethra, these tumors can be difficult to image using related art techniques, such as MRI, due to inconsistent ratios of choline plus creatine to citrate. Embodiments of the subject invention can therefore be used for improved monitoring for prostate cancer.

Embodiments of the subject invention can also be useful in cardiac imaging, where chemical shift imaging can be used to identify precursors to heart disease in patients with hereditary hemochromatosis (HHC). Chemical shift MRI with phosphorus-31P can enable the detection of alterations of cardiac high-energy phosphate metabolism in patients with HHC. Such patients have a high risk of developing heart disease, but have not exhibited any prior evidence, so embodiments of the subject invention can improve early diagnosis rates.

The systems, methods, and processes described herein can be embodied as code and/or data. The software code and data described herein can be stored on one or more computer-readable media, which may include any device or medium that can store code and/or data for use by a computer system. When a computer system reads and executes the code and/or data stored on a computer-readable medium, the computer system performs the methods and processes embodied as data structures and code stored within the computer-readable storage medium.

It should be appreciated by those skilled in the art that computer-readable media include removable and non-removable structures/devices that can be used for storage of information, such as computer-readable instructions, data structures, program modules, and other data used by a computing system/environment. A computer-readable medium includes, but is not limited to, volatile memory such as random access memories (RAM, DRAM, SRAM); and non-volatile memory such as flash memory, various read-only-memories (ROM, PROM, EPROM, EEPROM), magnetic and ferromagnetic/ferroelectric memories (MRAM, FeRAM), and magnetic and optical storage devices (hard drives, magnetic tape, CDs, DVDs); network devices; or other media now known or later developed that is capable of storing computer-readable information/data. Computer-readable media should not be construed or interpreted to include any propagating signals.

The subject invention includes, but is not limited to, the following exemplified embodiments.

Embodiment 1. An imaging method, comprising:
providing nanoparticles to a sample to be imaged;
using a radiation source to excite the nanoparticles; and
imaging the sample using magnetic resonance imaging (MRI) to obtain localization information of the nanoparticles by measuring a change in a resonance parameter of the nanoparticles as a result of the excitation by the radiation source.

Embodiment 2. The imaging method according to embodiment 1, wherein the nanoparticles are nanophosphors.

Embodiment 3. The imaging method according to embodiment 2, wherein the nanophosphors are semiconducting crystals doped with lanthanide ions.

Embodiment 4. The imaging method according to any of embodiments 1-3, wherein the resonance parameter of the nanoparticles is T2 relaxation time.

Embodiment 5. The imaging method according to any of embodiments 1-4, wherein the radiation source is an X-ray source such that the nanoparticles are excited with X-ray radiation.

Embodiment 6. The imaging method according to any of embodiments 1-5, wherein the sample to be imaged is a biological sample.

Embodiment 7. The imaging method according to any of embodiments 1-6, wherein the sample is living tissue such that the method is performed *in vivo*.

Embodiment 8. The imaging method according to embodiment 7, wherein the living tissue is living tissue of a human patient.

Embodiment 9. The imaging method according to any of embodiments 7-8, wherein the living tissue is a brain or part of a brain.

Embodiment 10. The imaging method according to any of embodiments 1, 2, or 4-9, wherein the nanoparticles include $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$, $\text{MgGa}_2\text{O}_4:\text{Cr}^{3+}$, $\text{Gd}_2\text{O}_2\text{S}:\text{Tb}^{3+}$, $\text{CaMgSi}_2\text{O}_6:\text{Eu}^{2+}$, $\text{CaMgSi}_2\text{O}_6:\text{Mn}^{2+}$, $\text{CaMgSi}_2\text{O}_6:\text{Pr}^{3+}$, or a combination thereof.

Embodiment 11. The imaging method according to any of embodiments 1-3 or 5-10, wherein the resonance parameter is T1, T2, or T2*.

Embodiment 12. The imaging method according to any of embodiments 1-11, wherein imaging the sample using MRI to obtain localization information of the nanoparticles by measuring a change in a resonance parameter of the nanoparticles as a result of the excitation by the radiation source comprises measuring the resonance parameter of the nanoparticles before and after excitation by the radiation source.

Embodiment 13. The imaging method according to any of embodiments 1-4 or 6-12, wherein the radiation source is an ultraviolet (UV) source such that the nanoparticles are excited with UV radiation.

Embodiment 14. The imaging method according to any of embodiments 1-13, further comprising obtaining computed tomography (CT) data from the sample simultaneously while imaging the sample using MRI.

Embodiment 15. An imaging system, comprising:
a radiation source configured to supply radiation to nanoparticles provided within a sample to be imaged;
an MRI machine configured to obtain a magnetic resonance image of the sample before and after excitation by the radiation source; and
a processor configured to determine localization information of the nanoparticles provided within the sample by measuring a change in a resonance parameter of the nanoparticles as a result of the excitation by the radiation source.

Embodiment 16. The imaging system according to embodiment 15, wherein the nanoparticles are nanophosphors.

Embodiment 17. The imaging system according to embodiment 16, wherein the nanophosphors are semiconducting crystals doped with lanthanide ions.

Embodiment 18. The imaging system according to any of embodiments 15-17, wherein the resonance parameter of the nanoparticles is T2 relaxation time.

Embodiment 19. The imaging system according to any of embodiments 15-18, wherein the radiation source is an X-ray source configured to supply X-ray radiation to the nanoparticles.

Embodiment 20. The imaging system according to any of embodiments 15-19, wherein the sample to be imaged is a biological sample.

Embodiment 21. The imaging system according to any of embodiments 15-20, wherein the sample is living tissue such that the system is capable of performing *in vivo* imaging.

Embodiment 22. The imaging system according to embodiment 21, wherein the living tissue is living tissue of a human patient.

Embodiment 23. The imaging system according to any of embodiments 21-22, wherein the living tissue is a brain or part of a brain.

Embodiment 24. The imaging system according to any of embodiments 15, 16, or 18-23, wherein the nanoparticles include $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$, $\text{MgGa}_2\text{O}_4:\text{Cr}^{3+}$, $\text{Gd}_2\text{O}_2\text{S}:\text{Tb}^{3+}$, $\text{CaMgSi}_2\text{O}_6:\text{Eu}^{2+}$, $\text{CaMgSi}_2\text{O}_6:\text{Mn}^{2+}$, $\text{CaMgSi}_2\text{O}_6:\text{Pr}^{3+}$, or a combination thereof.

Embodiment 25. The imaging system according to any of embodiments 15-17 or 19-24, wherein the resonance parameter is T1, T2, or T2*.

Embodiment 26. The imaging system according to any of embodiments 15-18 or 20-25, wherein the radiation source is a UV source configured to supply UV radiation to the nanoparticles.

Embodiment 27. The imaging system according to any of embodiments 15-26, further comprising a computed tomography mechanism integrated with the MRI machine to provide an integrated CT-MRI machine configured to simultaneously obtain CT data and MRI data from the sample.

A greater understanding of the present invention and of its many advantages may be had from the following examples, given by way of illustration. The following examples are illustrative of some of the methods, applications, embodiments and variants of the present

invention. They are, of course, not to be considered as limiting the invention. Numerous changes and modifications can be made with respect to the invention.

EXAMPLE 1

Europium-doped aluminate oxide powders were scanned using MRI. Green Europium-doped aluminate oxide powder in an amount of 900 mg was mixed in 3 mL of deionized water. The powder was excited using UV for 30 minutes. Violet europium-doped aluminate oxide powder in an amount of 900 mg was also mixed in 3 mL of deionized water and excited using UV for 30 minutes. Figure 5 shows an image of the bottles of the green and violet powders. MRI scans were run at time = 0, 1 hour, 2 hours, and about 12 hours. Tripilot scanning was used. RAREVTR (8 repetition time (TR)) pulse sequencing was used to measure T1, and multi-slice multi-echo (MSME) (16 echo time (TE)) was used to measure T2 relaxation time.

The powders quickly settled out of the solution, in less than 5 minutes. Figure 6 shows an image of the powders in the water. The water seemed to “quench” the observable phosphorescence, and after some time (about 12-24 hours), the powders became more of a paste than a slurry. Interactions between the water and the powders seemed to be limited.

Table 1 shows the T2 times for the powders initially and after 20 hours. Figure 7 shows the values from Table 1 in bar-graph form. Tube 1 was for the violet powder, and tube 2 was for the green powder. For each tube, the bar on the left represents the initial T2, and the bar on the right represents the T2 after 20 hours. Though a large difference was seen for the violet powder in particular, this was probably due to the stark difference from slurry to paste.

Table 1. T2 values for Example 1

Tube Number	Tube Contents	T2 time @ t=0h	T2 time @ t = 20h	Percent change
1	Violet Powder	235.142	229.97	2.199522
2	Green Powder	225.767	16.6941	92.60561

EXAMPLE 2

Nanoparticles at different densities were imaged. Five solutions having $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$ nanoparticles at different concentrations were made using standard serial dilution methods. A first control of water doped with CuSO_4 and a second control of deionized water were also made. These seven samples were made in tubes, and are shown in Figures 9-11. The numerical labels are as follows: 1 - control 1 (water doped with CuSO_4); 2 - $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$ nanoparticles at a density of 10 mg/mL; 3 - $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$ nanoparticles at a density of 5 mg/mL; 4 - $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$ nanoparticles at a density of 2.5 mg/mL; 5 - $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$ nanoparticles at a density of 1.25 mg/mL; 6 - $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$ nanoparticles at a density of 0.625 mg/mL; and 7 - control 2 (deionized water). Tripilot scanning was used. Pre-excitement was performed by MSME (16 echoes), and T2 was measured (4.5 minutes). Micro-CT irradiation was performed at 45 kVp and 88 mA for 7.7 minutes. Tripilot was used again, and then post-excitement MSME (16 echoes) was performed. The scale used to measure the particles had limited resolution, and the particles displayed poor solubility in the water, settling within 5 minutes. The micro-CT step experienced trouble with sample placement, and some samples fell out of the holder, leading to re-irradiation.

Table 2 shows the T2 times for the samples pre-excitation and post-excitation (all T2 times are listed in milliseconds (ms)). Figure 13 shows the values from Table 2 in bar-graph form. The tube numbers are displayed in Table 2 and, for each tube, the bar on the left represents the pre-excitation T2, and the bar on the right represents the post-excitation T2. Figure 14 shows the MRI images of the tubes before (left side) and after (right side)

excitation. Referring to Table 2 and Figure 13, significant differences were observed in T2 before and after excitation. The trend is counterintuitive (i.e., unexpected) in that lesser concentrations of nanophosphors (NPs) show greater change. Control 2 (deionized water) also showed a significant change.

Table 2. T2 values for Example 2

Tube Number	Tube Contents (NPs: LiGa₅O₈:Cr³⁺)	T2 pre-excitation (ms)	T2 post-excitation (ms)	Percent change
1	Doped water (CuSO ₄)	169.246	168.861	0.23%
2	10 mg/ml NPs	314.073	312.743	0.42%
3	5 mg/ml NPs	306.306	294.43	3.88%
4	2.5 mg/ml NPs	330.856	311.922	5.72%
5	1.25 mg/ml NPs	329.828	304.1	7.80%
6	0.625 mg/ml NPs	350.332	279.744	20.15%
7	Deionized Water	340.574	298.402	12.38%

EXAMPLE 3

The same experiment from Example 2 was run again, only this time, the seven tubes were as follows: 1 - control (water doped with CuSO₄); 2 - LiGa₅O₈:Cr³⁺ nanoparticles at a density of 10 mg/mL (excited); 3 - LiGa₅O₈:Cr³⁺ nanoparticles at a density of 10 mg/mL; 4 - empty; 5 - LiGa₅O₈:Cr³⁺ nanoparticles at a density of 10 mg/mL; 6 - LiGa₅O₈:Cr³⁺ nanoparticles at a density of 10 mg/mL (excited); and 7 - empty. That is, the density of the LiGa₅O₈:Cr³⁺ nanoparticles was the same in tubes 2, 3, 5, and 6, with tubes 2 and 6 having excited nanoparticles. Figure 18 shows an axial image of tubes 1-7. Figures 15-17 show images of equipment used in this experiment. A more sensitive scale was used compared to that used in Example 2. The particles again settled within 5 minutes. The T2 measurements varied greatly within each sample depending on ROI location (NPs settled on bottom versus water in center).

Table 3 shows the T2 times for the samples pre-excitation (outer ROI), pre-excitation (inner ROI), post-excitation (outer ROI), and post-excitation (inner ROI) (all T2 times are

listed in microseconds (ms)). Figure 19 shows MRI images of the tubes. Figure 21A shows a bar graph of the T2 relaxation time for an outer ROI for 10 mg/mL excited NPs (left bar) and 10 mg/mL unexcited NPs (right bar); this is for settled particles. Figure 21B shows a bar graph of the T2 relaxation time for an inner ROI for 10 mg/mL excited NPs (left bar) and 10 mg/mL unexcited NPs (right bar); this is for bulk water. Figure 20 shows an MRI image with outlining for the ROI used for the data in Figures 21A and 21B.

Figure 23A shows a bar graph of the T2 relaxation time for settled NPs ROI for 10 mg/mL excited NPs (left bar) and 10 mg/mL unexcited NPs (right bar). Figure 23B shows a bar graph of the T2 relaxation time for an outer ROI for 10 mg/mL excited NPs (left bar) and 10 mg/mL unexcited NPs (right bar); this is for bulk water. Figure 22 shows an MRI image with outlining for the ROI used for the data in Figures 23A and 23B.

Table 3. T2 values for Example 3

Tube Number	Tube Contents	T2 pre-excitation (Outer ROI) (ms)	T2 pre-excitation (Inner ROI) (ms)	T2 post-excitation (Outer ROI) (ms)	T2 post-excitation (Inner ROI) (ms)	Percent Change (Outer ROI)	Percent Change (Inner ROI)
1	Doped water (CuSO ₄)		126.683		120.208		5.11%
2	10 mg/ml NPs - Excited	54.8117	61.6567	44.195	52.8227	19.37%	14.33%
6	10 mg/ml NPs - Excited	34.022	53.0842	57.9258	64.7838	70.26%	22.04%
3	10 mg/ml NPs	19.5639	43.385	31.786	72.6739	62.47%	67.51%
5	10 mg/ml NPs	25.3117	81.3098	21.0454	51.6328	16.86%	36.50%

EXAMPLE 4

All the nanophosphors used were LiGa₅O₈:Cr³⁺ nanophosphors having a size of <100 nm. These particles are highly non-colloidal, settling out of an aqueous solution within 2 minutes. Long-term settling (> 1 hour) resulted in hypo-intense regions within the MRI images indicative of a lack of hydrogen molecules to give readable MRI signals. For this reason, the samples had to be agitated before each set of acquisitions and excitations. This resulted in decreased control over the particle distribution within any given sample between before- and after-excitations.

The measured phosphor content in each sample through bulk concentration calculations may have been misrepresentative of the true local concentrations that resulted

from the quick settling behavior of the nanophosphors when placed in water. Thus, small amounts of “dispersed” nanophosphors were added in water to a 3 mm diameter capillary tube. After the particles visibly settled, the supernatant water was removed from the sample and more “dispersed” nanophosphors were added to the sample. This stepwise addition of nanophosphors continued until the capillary tube had approximately a 7-mm tall column of nanophosphors. After the required volume was achieved, the remaining supernatant was kept on top of the net volume of nanophosphors to be used as the proton source for all MRI measurements.

Two samples were made for each trial (X-ray excited, UV excited, unexcited nanophosphors). The unexcited samples were not subjected to any X-ray excitation during the experiments. Hereafter the scans of this example are referred to as either “before-excitation” or “after-excitation” to distinguish the two time points of the scans even though not all samples in the “after-excitation” scan underwent excitation. Additionally, a capillary tube was filled with water to serve as a reference. The seven capillary tubes were then arranged in a hexagonal shape, wrapped into a bundle with parafilm, and placed in a small polystyrene tube surrounded by Cu₂SO₄-doped water. Figures 30A and 30B show side and axial views, respectively, of the capillary tube arrangement (can be referred to as the phantom arrangement) in a polystyrene holder. Figure 30C shows the specific placement of the samples as placed in the MRI imager.

The X-ray excited samples were prepared in a Scanco vivaCT 40 and scanned at a tube voltage of 70 kVp and tube current of 114 μ A. The pitch and number of projections were set to have the scan run for at least 15 minutes according to the imaging software.

The UV excited samples were prepared on the bottom of a Spectrolinker XL-1000 device, which produces UV radiation at 254 nm, 2 A, and 120 V. The samples were irradiated for 15 minutes.

To verify the persistent luminescence from the nanophosphors, preliminary observations were made by Nikon TE2000 wide-field microscopy (invertedepi-fluorescence mode; 4X objective lens) with an emission filter (bandwidth 60 nm at 720 nm, Chroma). The microscope was housed in a transparent plastic chamber, in which a “dark-room” was created by black-cloth coverage. For homogenous close-up stimulation, the continuous-wave laser stimulation source at 635 nm (single-mode semiconductor CW laser, S1FC635, Thorlabs) was coupled to a fiber cable (OceanOptics) and a megapixel ultra-low-

distortion compound lens (2/3", 25 mm, C-mount, M2518-MPW2, Computer). The laser stimulation power was set at 2 mW for each exposure time of 5 seconds.

The respective phantoms were placed in a Bruker 13 cm, 7T horizontal bore MRI scanner, centered in a 23 mm RF coil. Special care was taken to preclude air bubbles that were present in the regions to be imaged. Prior to the T2 experiments, the position of each phantom was optimized and established using a gradient echo TriPilot scan. The local magnetic field about the field of view (FOV) was further optimized using the FieldMap routine. The T2 experiments consisted of a multi-spin, multi-echo protocol in which the echo times (TEs) were varied as a train of 16 equally spaced echoes of 10.5 msec with a repetition time (TR) of 2000 msec. The FOV was 20 mm x 20 mm with an in-plane resolution of 0.156 mm x 0.156 mm and slice thickness of 1.25 mm. Six slices were taken to collect as many usable image data as possible. These parameters led to a scan time of 2 minutes and 13 seconds. The resulting dataset from a T2 experiment was processed as a 4-D matrix with dimensions of 128 x 128 x 6 x 16 (x, y, z, TE) whose voxel values represent signal intensity modeled by Equation 1:

$$S = k \rho \left(1 - \exp \left(-\frac{TR}{T_1} \right) \right) \exp \left(-\frac{TE}{T_2} \right), \quad (1)$$

where S is the amplitude of the signal, k is a proportionality constant that depends on the machine and RF coil, the unknown T_1 , T_2 (same as T_2), and ρ (proton density) can be imaged at will.

The 4-D dataset was pixel-wise fit into Equation 2 across the TE dimension using the Image Sequence Analysis tool of the ParaVision software (v5.1) as supplied by Bruker:

$$S = A \exp \left(-\frac{TE}{T_2} \right) + c. \quad (2)$$

Equation 2 is a simplified version of Equation 1 with A being the machine specific proportionality constant k multiplied by the sample specific constant ρ (proton density) and the $(1 - \exp(-TR/T_1))$ function, since TR was held constant in the experiment. The resulting dataset from this analysis step is a 3-D matrix with dimensions of 128 x 128 x 6, and can be referred to as the T_2 map. This dataset was further reduced by manual selection of the slice that contained the largest number of usable samples. Samples were considered usable

when a clear interface could be seen between the nanophosphor and water regions. Because of this restriction, one UV excited sample and one unexcited sample were excluded from the analysis because none of the slices contained a usable interface. An additional output from the ParaVision T_2 mapping software is the intensity image that was also used as the proton-density-weighted image, although it is more representative of the image of the raw intensities at the first TE.

Taking into account the nanophosphor settling as well as the inner- and outer-sphere relaxation mechanisms of contrast agents modeled by Solomon-Bloembergen- Morgan (SBM) relaxation theory, the change in T_2 relaxation may be found at the interface between the nanophosphor and water in the samples. Analysis of the interface was conducted using common image processing and segmentation algorithms including interpolation, Otsu thresholding, and Sobel edge detection. Some manual intervention was also used to select ROIs and choose the edges found to be representative of the nanophosphor-water interface. All of these techniques were implemented in a customized MATLAB code.

The Otsu thresholding and Sobel edge detection were performed on the proton-density-weighted ROIs. This outcome was treated as the “true” interface between nanophosphor deposit and water. Once the edges were identified, they were mapped to the T_2 image, and the values from the pixels along the edge were averaged. To reduce the measurement error, edges were manually restricted to the areas of qualitative contrast between nanophosphors and water. Figure 33 shows a diagram of the workflow of data analysis. This same pipeline was repeated four more times for each sample adjusting the Otsu threshold value by 2 grayscale units in both the water (Threshold – value) and NP (Threshold + value) directions to test the robustness of the data trends.

Figures 31A and 31B show the microscopy images with laser stimulation off and on, respectively. The laser stimulation on-off observations were repeated several times with the NPs sample intentionally exposed to the room-light illumination between each trial. The persistent luminescence was subject to negligible leakage under room-light illumination while the CW laser illumination could effectively stimulate the release of the stored UV energy for narrowband luminescence re-emissions at 716 nm.

Figures 32 and 34-36 show comparison of mean T_2 time constants along the water-NP interface before excitation and after excitation. Figures 32A, 34A, 35A, and 36A each

shows an image of nanophosphors and a bar graph showing mean T2 relaxation time. In each of Figures 32A, 34A, 35A, and 36A, the left bar is before excitation and the right bar is after excitation. Figures 32B, 34B, 35B, and 36B each shows an image of the sample before excitation, and Figures 32C, 34C, 35C, and 36C each shows an image of the sample from Figures 32B, 34B, 35B, and 36B, respectively, after excitation.

Referring to Figures 32 and 34-36, an effect from excitation is suggested. In each of the excited samples (UV - Figure 34, X-ray1 - Figure 35, X-ray2 - Figure 36), a decrease in mean T2 is possibly evident although the standard deviations overlap. The unexcited control (Figure 32), however, shows a slight but insignificant increase in mean T2 along the edge as seen in Figure 32. With this control in mind, excitation of the nanoparticle slurries via UV and X-ray seem to show a trend toward a decreased T2 after excitation relative to before excitation.

Further mean comparisons were made with adjusted threshold values. In this analysis, the edges were calculated after implementing adjusted threshold values and calculating the mean T2s along the new edges. Figure 37 shows an image of nanoparticles (top left), a bar graph showing mean T₂ relaxation time (top right), and images of samples. Figure 38 also shows an image of nanoparticles (top left), a bar graph showing mean T₂ relaxation time (top right), and images of samples. In each of Figures 37 and 38, the bars and the images from left to right are Thresh-2, Thresh-1, Thresh, Thresh+1, and Thresh+2. Referring to Figures 37 and 38 T2 increased when edges were taken more toward the water region (Thresh – value), and T2 decreased when edges were take more toward the NP region (Thresh + value).

Direct comparison for each of these edges was made to see if a change could be consistently detected between before- and after-excitation images as the edge was shifted into either of the regions. Figures 39A-39D show that in the excited samples (UV - Figure 39B, X-ray1 - Figure 39C, X-ray2 - Figure 39D) the mean differences between the before- and after-excitation samples were increased as the edge moves further into the water regions. The unexcited control (Figure 39A) also shows an increase in the mean difference between before- and after-excitation into the water region, but the trend for the unexcited control is not as consistent and distinct as for the excited counterparts.

The data advantageously show that the water coupled to nanophosphor slurries and excited by ionizing radiation such as UV or X-ray for 15 minutes is detected as

having reduced T_2 relaxation time constants. Changes in relaxometry were most clearly observed along the edge of the slurry-water interface with changes extending somewhat into the bulk water phase. This is consistent with the physical understanding of the redistribution of electrons within semiconductor nanophosphors and the subsequent effects on nuclear relaxation. The acquisition and analysis of the data may be considered complicated by the non-colloidal behavior of the nanoparticles employed. The nanophosphors used in this example can remain in a stable X-ray excited state over long periods of time, thereby allowing for the particles to be excited outside of the MRI machine and remain excited during the high-resolution imaging sessions. Despite this vital advantage, these nanophosphors may behave poorly in aqueous environments. Within minutes of dispersing the particles in the water, more than 90% of the particles had settled to the bottom of the capillary tubes. After allowing the particles to settle for about an hour, water being excluded from the particle slurry was seen by a loss of MRI readable signal as a function of time.

The non-colloidal behavior can potentially lead to issues with sample control, stability, or homogeneity. While a robust characterization of a colloidal suspension may have some advantages, qualitative changes in water relaxation about the nanoparticle slurry-bulk water interface were detected once the samples were allowed to settle for 5-10 min before undergoing MRI scans. Variations in the water-slurry interfaces among the samples and scans of the same sample pre- and post-X-ray treatment can result in measurement variations. Further measurement error, possibly resulting in lower measured changes or larger standard deviations, may have also resulted from variable NP concentrations in the water regions of each sample. Regardless of the source of the variation, overlapping standard deviation ranges between samples before- and after-excitation can indicate a decrease in statistical significance.

Any experimental complications caused by non-colloidal nanophosphors can be mitigated through the use of nanophosphors (e.g., semiconducting nanophosphors) that can be more easily suspended or remain colloidal in aqueous solutions. Techniques that can be used according to embodiments of the subject invention for improving the water compatibility include milling or crystal growth to smaller particle sizes, coating, or conjugating the nanophosphors to hydrophilic polymers. These techniques also open doors for specific targeting of these nanophosphors to cells and proteins. Such conjugation could

potentially decrease the direct interaction of water with the nanophosphor's electron distribution, resulting in less change in T2 after UV or X-ray excitation. Enhanced experimental control and robust statistical analysis methods such as paired t-tests can be used to help quantitatively demonstrate the effect of UV or X-ray excitation of nanophosphors on the T2 relaxation of surrounding water protons in a biologically relevant model.

Additionally, uncertainties in the T2 constants for water were high due to highly-efficient but sub-optimal sampling of its intensity during the relaxation period. The max TE used was about 180 msec, and, therefore, trying to fit water T2 constants that are greater than 300 msec may have resulted in some minor errors that could be improved with a different imaging protocol. If two primary T2s are present, a second T2 experiment with better TE sampling can be used for better T2 fits with less variation from voxel to voxel in both types of ROIs.

Because of the low resolution of the images at the sample level, each image underwent bicubic interpolation. Such methods are accepted for approximating data among measured points, though the various thresholds and subsequent edges calculated may have approximation errors during the T2 averaging. Also, to make sure if the change in T2s shown in the data is a result of the nanophosphor excitation, a repeated measurement with the same samples after discharging the nanophosphors can be performed. The persistence shown by these particles makes true discharge of the nanophosphors challenging.

As shown in this example, X-rays can be used to alter measured MRI signals through the use of nanophosphors (e.g., semiconducting nanophosphors). The link between X-rays, nanophosphors, and MRI can be utilized to advance imaging technology and deepen the understanding of multi-physics coupling.

EXAMPLE 5

About 250 μL of nanophosphor ($\text{Gd}_2\text{O}_2\text{S}:\text{Tb}^{3+}$) suspensions of varying concentrations (0.1, 0.2, 0.4, and 0.8 mg/mL) in 0.5% agar were pipetted into a pair of glass slides separated by 0.75 mm plastic spacers and allowed to gel. This was done to verify that the UV LED source used for the remainder of this example was capable of causing the nanophosphors to emit phosphorescence. A Nikon TE2000 wide-field microscope (inverted epi-fluorescence mode; 10X objective lens) with an emission filter (bandwidth 40 nm at 535 nm, Chroma) was

used to capture phosphorescence images both with and without UV excitation. Microscopy was performed in a dark environment, and the UV LED fibers were placed directly in the gels. Phosphorescence was qualitatively measured by subtracting the UV-off image from the UV-on image. Figure 40 shows a result image from subtracting an image of 0.1mg/mL $\text{Gd}_2\text{O}_2\text{S:Tb}^{3+}$ in 0.5% agar without UV from an image with UV. UV caused an increase in phosphorescence signal at the end of the fiber optic cables (plot profile inlaid). The full width at half maximum (FWHM) of the phosphorescence was 104 μm , indicating that any changes in MRI parameters should occur within about 100 μm of the fiber optic end.

The same stock suspensions used for the phosphorescence verification were then pipetted into 5 mm NMR tubes, capped, and placed within larger cuvettes filled with Cu_2SO_4 -doped water. The fiber optical leads were thread through small holes in the caps of both the cuvette and nuclear magnetic resonance (NMR) tubes and centered by the placement of a small piece of foam in the top of the NMR tubes. Figure 12 shows a schematic side view (left) and a schematic axial view (right) of a tube. The leads were placed directly into the agar gel and held in place by tape and parafilm.

Each sample was placed in a 23-mm RF coil and centered in a Bruker 13cm, 7T horizontal bore MRI scanner. T1, T2, and T2* were quantitatively measured and mapped within the samples using the same protocols described in Example 4.

T2 was measured with a train of 16 TEs of equally spaced echoes of 10.5 ms and a TR of 1042.8 ms. Anisotropic voxels were taken to reduce the scan time with 256 px in the read-out direction and 128 px in the P1 direction. Because the field of view was 1.8 mm by 1.4 mm, the read-out resolution was 70 $\mu\text{m}/\text{px}$ and the P1 resolution was 109 $\mu\text{m}/\text{px}$. Also, the slice thickness used was 1.2 5mm. This geometry reduced the scan time to 2 min and 13 seconds. These scans were repeated with UV irradiation to test the effects of nanophosphor excitation and phosphorescence on the MRI parameters.

Figure 40 shows the verification of emission phosphorescence under UV irradiation. Only the 0.1 mg/mL concentration suspension is shown, but all of the suspensions showed similar phosphorescence signatures. UV light is quickly attenuated in the agar samples, which is shown by the relatively shallow phosphorescence. This result indicates where MRI parameter changes are most likely to occur: within a few hundred microns of the fiber optic end.

Figure 41 shows the intrinsic concentration-dependent contrast modulation by the $\text{Gd}_2\text{O}_2\text{S:Tb}^{3+}$. Referring to Figure 41, T2 measurements decreased as the $\text{Gd}_2\text{O}_2\text{S:Tb}^{3+}$ concentration increased. Though not shown in Figure 41, T1 and T2* also decreased as nanophosphor concentration increased. The results may have been limited due to slice thickness being about 6-fold wider than the fiber optic width. Results may have also been limited by the combination of shallow UV penetration through agar as well as the resolution of the MRI. Smaller slice thickness would likely give even more improved results. Also, the MRI parameters can be measured before, during, and after UV-irradiation. In addition, higher power UV and/or higher efficiency nanophosphors can be used to give even more improved results.

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application.

All patents, patent applications, provisional applications, and publications referred to or cited herein (including those in the "References" section) are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

REFERENCES

- Carpenter CM, Sun C, Pratz G, Liu H, Cheng Z, et al. (2012) Radioluminescent nanophosphors enable multiplexed small-animal imaging. *Opt Express* 20: 11598–11604 (<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3482915&tool=pmcentrez&rendertype=abstract>).
- Qin J, Peng C, Zhao B, Ye K, Yuan F, et al. (2014) Noninvasive detection of macrophages in atherosclerotic lesions by computed tomography enhanced with PEGylated gold nanoparticles. *Int J Nanomedicine* 9: 5575.
- Naha PC, Al Zaki A, Hecht E, Chorny M, Chhour P, et al. (2014) Dextran coated bismuth–iron oxide nanohybrid contrast agents for computed tomography and magnetic resonance imaging. *J Mater Chem B* 2: 8239–8248.
- Cong W, Wang C, Wang G (2014) Stored Luminescence Computed Tomography. *Appl Opt* 53: 5672–5676 (<http://arxiv.org/abs/1309.3585>).
- Cong W, Liu F, Wang C, Wang G (2014) X-ray micro-modulated luminescence tomography (XMLT). *Opt Express* 22: 5572–5580.
- Chuang Y-J, Zhen Z, Zhang F, Liu F, Mishra JP, et al. (2014) Photostimulable Near-Infrared Persistent Luminescent Nanoprobes for Ultrasensitive and Longitudinal Deep-Tissue Bio-Imaging. *Theranostics* 4: 1112.
- Laurent S, Vander Elst L, Muller RN (2009) Lanthanide complexes for magnetic resonance and optical molecular imaging. *Q J Nucl Med Mol imaging Off Publ Ital Assoc Nucl Med (AIMN)[and] Int Assoc Radiopharmacol (IAR),[and] Sect Soc of.* 53: 586–603.
- Elster AD (2014) Advanced Relaxation Theory. ELSTER LLC (<http://www.mri-q.com/solomon-bloembergen.html>).
- F. Liu, W. Yan, Y.-J. Chuang, Z. Zhen, J. Xie, and Z. Pan, “Photostimulated near-infrared persistent luminescence as a new optical read-out from Cr³⁺-doped LiGa₅O₈,” *Sci. Rep.*, vol. 3, p. 1554, Jan. 2013.
- T. Maldiney, A. Lecointre, B. Viana, A. Bessière, M. Bessodes, D. Gourier, C. Richard, and D. Scherman, “Controlling electron trap depth to enhance optical properties of persistent luminescence nanoparticles for in vivo imaging,” *J. Am. Chem. Soc.*, vol. 133, no. 30, pp. 11810–5, Aug. 2011.
- S. Laurent, L. Vander Elst, and R. N. Muller, “Lanthanide complexes for magnetic resonance and optical molecular imaging,” *Q. J. Nucl. Med. Mol. imaging Off. Publ. Ital.*

Assoc. Nucl. Med. (AIMN)[and] Int. Assoc. Radiopharmacol. (IAR),[and] Sect. Soc. of., vol. 53, no. 6, pp. 586–603, 2009.

- H. Chen, T. Moore, B. Qi, D. C. Colvin, E. K. Jelen, D. A. Hitchcock, J. He, O. T. Mefford, J. C. Gore, and F. Alexis, “Monitoring pH-triggered drug release from radioluminescent nanocapsules with X-ray excited optical luminescence,” *ACS Nano*, vol. 7, no. 2, pp. 1178–1187, 2013.

- M. Getzin, Y. Xu, A. Rao, S. Madi, A. Bahadur, M. R. Lennartz, and G. Wang, “Carotid plaque characterization using CT and MRI scans for synergistic image analysis,” in *SPIE Optical Engineering+ Applications*, 2014, p. 92121B–92121B.

- M. Getzin, L. Gjestebj, Y.-J. Chuang, S. McCallum, W. Cong, C. Wang, Z. Pan, G. Dai, and G. Wang, “A Pilot Study on Coupling CT and MRI through Use of Semiconductor Nanoparticles,” *arXiv Prepr. arXiv1412.7554*, 2014.

CLAIMS

What is claimed is:

1. An imaging method, comprising:
providing nanoparticles to a sample to be imaged;
using a radiation source to excite the nanoparticles; and
imaging the sample using magnetic resonance imaging (MRI) to obtain localization information of the nanoparticles by measuring a change in a resonance parameter of the nanoparticles as a result of the excitation by the radiation source.
2. The imaging method according to claim 1, wherein the nanoparticles are nanophosphors.
3. The imaging method according to claim 2, wherein the nanophosphors are semiconducting crystals doped with lanthanide ions.
4. The imaging method according to any of claims 1-3, wherein the resonance parameter of the nanoparticles is T2 relaxation time.
5. The imaging method according to any of claims 1-4, wherein the radiation source is an X-ray source such that the nanoparticles are excited with X-ray radiation.
6. The imaging method according to any of claims 1-5, wherein the sample to be imaged is a biological sample.
7. The imaging method according to any of claims 1-6, wherein the sample is living tissue such that the method is performed *in vivo*.
8. The imaging method according to claim 7, wherein the living tissue is living tissue of a human patient.

9. The imaging method according to any of claims 7-8, wherein the living tissue is a brain or part of a brain.

10. The imaging method according to any of claims 1, 2, or 4-9, wherein the nanoparticles include $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$, $\text{MgGa}_2\text{O}_4:\text{Cr}^{3+}$, $\text{Gd}_2\text{O}_2\text{S}:\text{Tb}^{3+}$, $\text{CaMgSi}_2\text{O}_6:\text{Eu}^{2+}$, $\text{CaMgSi}_2\text{O}_6:\text{Mn}^{2+}$, $\text{CaMgSi}_2\text{O}_6:\text{Pr}^{3+}$, or a combination thereof.

11. The imaging method according to any of claims 1-3 or 5-10, wherein the resonance parameter is T1, T2, or T2*.

12. The imaging method according to any of claims 1-11, wherein imaging the sample using MRI to obtain localization information of the nanoparticles by measuring a change in a resonance parameter of the nanoparticles as a result of the excitation by the radiation source comprises measuring the resonance parameter of the nanoparticles before and after excitation by the radiation source.

13. The imaging method according to any of claims 1-4 or 6-12, wherein the radiation source is an ultraviolet (UV) source such that the nanoparticles are excited with UV radiation.

14. The imaging method according to any of claims 1-13, further comprising obtaining computed tomography (CT) data from the sample simultaneously while imaging the sample using MRI.

15. An imaging system, comprising:
a radiation source configured to supply radiation to nanoparticles provided within a sample to be imaged;
an MRI machine configured to obtain a magnetic resonance image of the sample before and after excitation by the radiation source; and
a processor configured to determine localization information of the nanoparticles provided within the sample by measuring a change in a resonance parameter of the nanoparticles as a result of the excitation by the radiation source.

16. The imaging system according to claim 15, wherein the nanoparticles are nanophosphors.

17. The imaging system according to claim 16, wherein the nanophosphors are semiconducting crystals doped with lanthanide ions.

18. The imaging system according to any of claims 15-17, wherein the resonance parameter of the nanoparticles is T2 relaxation time.

19. The imaging system according to any of claims 15-18, wherein the radiation source is an X-ray source configured to supply X-ray radiation to the nanoparticles.

20. The imaging system according to any of claims 15-19, wherein the sample to be imaged is a biological sample.

21. The imaging system according to any of claims 15-20, wherein the sample is living tissue such that the system is capable of performing *in vivo* imaging.

22. The imaging system according to claim 21, wherein the living tissue is living tissue of a human patient.

23. The imaging system according to any of claims 21-22, wherein the living tissue is a brain or part of a brain.

24. The imaging system according to any of claims 15, 16, or 18-23, wherein the nanoparticles include $\text{LiGa}_5\text{O}_8:\text{Cr}^{3+}$, $\text{MgGa}_2\text{O}_4:\text{Cr}^{3+}$, $\text{Gd}_2\text{O}_2\text{S}:\text{Tb}^{3+}$, $\text{CaMgSi}_2\text{O}_6:\text{Eu}^{2+}$, $\text{CaMgSi}_2\text{O}_6:\text{Mn}^{2+}$, $\text{CaMgSi}_2\text{O}_6:\text{Pr}^{3+}$, or a combination thereof.

25. The imaging system according to any of claims 15-17 or 19-24, wherein the resonance parameter is T1, T2, or T2*.

26. The imaging system according to any of claims 15-18 or 20-25, wherein the radiation source is a UV source configured to supply UV radiation to the nanoparticles.

27. The imaging system according to any of claims 15-26, further comprising a computed tomography mechanism integrated with the MRI machine to provide an integrated CT-MRI machine configured to simultaneously obtain CT data and MRI data from the sample.




FIG. 1





FIG. 2A

3/35






FIG. 3

5/35




FIG. 4



FIG. 5

7/35




FIG. 6




FIG. 7




FIG. 8

9/35



FIG. 9




FIG. 10




FIG. 11

10/35




FIG. 12

Nanoparticle T2 Resonance Changes




FIG. 13




FIG. 14A




FIG. 14B

12/35




FIG. 15




FIG. 16




FIG. 17

13/35




FIG. 18




FIG. 19

15/35




FIG. 20

16/35

T2 Relaxation of Settled Particles




FIG. 21A

T2 Relaxation of Bulk Water




FIG. 21B

17/35




FIG. 22

18/35

T2 Relaxation of Settled Particles




FIG. 23A

T2 Relaxation of Bulk Water




FIG. 23B




FIG. 24




FIG. 25A




FIG. 25B




FIG. 26




FIG. 27

24/35




FIG. 28




FIG. 29




FIG. 30A

FIG. 30B

FIG. 30C





FIG. 31A

FIG. 31B

27/35



FIGS. 32A-32C







FIG. 33



FIGS. 34A-34C



FIGS. 35A-35C



FIGS. 36A-36C




FIG. 37





FIG. 38



FIGS. 39A-39D

35/35




FIG. 40




FIG. 41

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2015/026919**A. CLASSIFICATION OF SUBJECT MATTER****G01R 33/20(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

G01R 33/20; G01R 33/00; A61B 6/00; A61N 2/00; G01R 33/48; G01R 33/44; A61K 49/10

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & keywords: metrology, diffraction order, map, intensity

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2006-0173362 A1 (TOMS et al.) 03 August 2006 See abstract, paragraphs [0049]–[0055], claims 1–3 and figures 1–6.	1–4, 15–18
Y	US 2007-0104650 A1 (CUNNINGHAM et al.) 10 May 2007 See abstract, paragraphs [0030]–[0031], claims 1–3 and figure 3.	1–4, 15–18
A	US 2008-0255403 A1 (VOEGELE et al.) 16 October 2008 See paragraphs [0027]–[0047], claims 1–7 and figures 1–6.	1–4, 15–18
A	US 2011-0148414 A1 (TEUGHELS et al.) 23 June 2011 See abstract, claims 1–9 and figures 3–10.	1–4, 15–18
A	US 2010-0259259 A1 (ZAHN et al.) 14 October 2010 See abstract, claims 1–23 and figures 1–20.	1–4, 15–18



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 July 2015 (29.07.2015)

Date of mailing of the international search report

29 July 2015 (29.07.2015)

Name and mailing address of the ISA/KR

International Application Division
Korean Intellectual Property Office
189 Cheongsu-ro, Seo-gu, Daejeon Metropolitan City, 302-701,
Republic of Korea

Facsimile No. +82-42-472-7140

Authorized officer

KANG, Sung Chul

Telephone No. +82-42-481-8405



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2015/026919**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 8,22
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims 8, 22 are unclear, because they refer to multiple dependent claims 7, 21 which do not comply with PCT Rule 6.4(a).
3. ☒ Claims Nos.: 5-7,9-14,19-21,23-27
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2015/026919

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2006-0173362 A1	03/08/2006	WO 2006-042233 A1 WO 2006-042233 A9	20/04/2006 29/06/2006
US 2007-0104650 A1	10/05/2007	US 7809424 B2	05/10/2010
US 2008-0255403 A1	16/10/2008	CA 2683635 A1 CN 101951962 A EP 2146751 A2 US 2008-0255414 A1 US 2008-0255425 A1 US 2008-0255459 A1 US 2008-0255460 A1 US 2008-0255537 A1 US 8062215 B2 US 8239007 B2 US 8239008 B2 WO 2008-128051 A2 WO 2008-128051 A3	23/10/2008 19/01/2011 27/01/2010 16/10/2008 16/10/2008 16/10/2008 16/10/2008 16/10/2008 22/11/2011 07/08/2012 07/08/2012 23/10/2008 28/10/2010
US 2011-0148414 A1	23/06/2011	EP 2273280 A1 EP 2331982 A1 EP 2344867 A1 EP 2682743 A1 GB 0906644 D0 JP 2012-50423 1A JP 2012-504247 A JP 5576869 B2 US 2012-0049847 A1 US 2013-0015857 A1 US 8283926 B2 US 8542014 B2 US 8816685 B2 WO 2010-037800 A1 WO 2010-037801 A1	12/01/2011 15/06/2011 20/07/2011 08/01/2014 03/06/2009 16/02/2012 16/02/2012 20/08/2014 01/03/2012 17/01/2013 09/10/2012 24/09/2013 26/08/2014 08/04/2010 08/04/2010
US 2010-0259259 A1	14/10/2010	US 2010-0019764 A1 US 8093896 B2 WO 2007-035871 A1 WO 2008-036412 A2 WO 2008-036412 A3	28/01/2010 10/01/2012 29/03/2007 27/03/2008 15/05/2008